Hopkins Testing New Uses For Improving Sight With Laser

July 03, 1997

Johns Hopkins researchers are testing a new laser operation that could do for farsighted eyeglass wearers what surgery has long offered the nearsighted: clear vision without glasses or contact lenses.

"Excimer laser surgery to gently sculpt the cornea--the clear `front window' of the eye that focuses incoming light, has the potential of opening laser treatment to millions of individuals," says Nada S. Jabbur, M.D., assistant professor of ophthalmology. About 6 percent of Americans are farsighted, and the condition usually affects people in their 40s, she says.

The procedure uses the first and only laser system to receive pre-market approval for the treatment of both nearsightedness and farsightedness with astigmatism. A person with astigmatism has wavy, distorted vision. The Hopkins investigators are using the system, called VISX Star Excimer Laser System, to reshape the corneas of volunteers.

"Using the laser, we treat the outer edges of the cornea to make the central area steeper," says Jabbur, the lead investigator for Wilmer Eye Institute. "This allows the cornea to focus light properly onto the retina, improving the person's sight without glasses."

"We are encouraged by the excellent results at Wilmer of the laser treatment to correct farsightedness, thus far," says Terrence P. O'Brien, M.D., director of refractive eye surgery. "The condition of farsightedness can be a real handicap, and the level of patient satisfaction after treatment has been very high."

Earlier studies done with the system showed excellent results for the farsighted, according to Jabbur. In one, in 1996, at the University of Ottawa Eye Institute, 96 percent attained 20/40 vision or better--vision good enough to pass a driver's test in most states without eyeglasses or contact lenses.

Candidates for clinical trials must be in good health, wear glasses or contact lenses and must not have had any form of eye surgery. In addition, patients should be willing to follow-up with periodic visits to Wilmer. To find out more about how to participate in these trials, potential volunteers can contact Mary Ann Millar, Wilmer Eye Institute, at (410)-614-2020.

The study is being funded by VISX Incorporated.

###





Johns Hopkins Medical Institutions' news releases are available on a PRE-EMBARGOED basis on EurekAlert at http://www.eurekalert.org and from the Office of Communications and Public Affairs' direct e-mail news release service. To enroll, call 410-955-4255 or send e-mail to bpalevic@welchlink.welch.jhu.edu or 76520.560@compuserve.com.

On a POST-EMBARGOED basis find them at http://hopkins.med.jhu.edu, http://infonet.welch.jhu.edu/news/news_releases, Newswise at http://www.ari.net/newswise or on CompuServe in the SciNews-MedNews library of the Journalism Forum under file extension ".jhm", Quadnet at http://www.quad-net.com or ScienceDaily at http://www.sciencedaily.com.

Johns Hopkins Medicine

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.